By vgreene, 19 March, 2020 No difference in median time to clinical improvement (LPV/r 16 days vs SOC 16 days) or 28-day mortality (LPV/r 19% vs SOC 25%); rate of detectable viral load similar between groups at all sampling timepoints; similar rates of ADRs (LPV/r 48% vs SOC 50%),
By vgreene, 19 March, 2020 Open-label RCT; 199 hospitalized pts (mean age, 58y) w/ confirmed SARS-CoV-2 and O2 sat ≤94% on RA randomized 1:1 to LPV/r 400 mg/100 mg bid x14 days plus SOC, or SOC alone; 13 days median time btwn sx onset and randomization; SOC group had higher rates o
By vgreene, 19 March, 2020 A Trial of Lopinavir Ritonavir in Adults Hospitalized With Severe Covid 19
By vgreene, 19 March, 2020 Randomized to daily losartan 25 mg PO daily or placebo x7 days (or to hospital discharge)
By switaschek, 19 March, 2020 GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report